A new dual therapy approach shows promise in fighting aggressive breast cancer by targeting tumors and cutting off their energy supply.
Aggressive breast cancer treatment tested in mice
Researchers in the United States are exploring a new method to treat one of the most aggressive forms of breast cancer by combining two approaches: attacking the tumor directly and cutting off the cancer cells’ energy supply. In experiments on mice, this method significantly reduced the spread of cancer to the lungs.Dual strategy shows promise in preclinical trials
A team from the Ohio State University Comprehensive Cancer Center tested a combination therapy using a drug called CD276-DM1, which targets a specific protein on cancer cells, and a mitochondrial gene therapy named cmLumiOpto. This dual approach slowed tumor growth and reduced the spread of cancer in preclinical models.Study published in medical journal
The findings were published in the journal Cell Reports Medicine on August 18, 2026. The research team explained that the combination of a targeted drug and a therapy that disrupts the energy production in cancer cells could offer a new way to fight triple-negative breast cancer, a particularly challenging form of the disease.Triple-negative breast cancer lacks standard treatments
Triple-negative breast cancer accounts for 10 to 15 percent of all breast cancers and does not have the hormone receptors or HER2 protein that other types do. This makes it less responsive to standard targeted therapies, leaving chemotherapy as the main option, which often leads to relapses within three years.
